GLP-1 Receptor Agonist Global Market Strategic Insights to 2034

GLP-1 Receptor Agonist Market Outlook for 2024 to 2034

The GLP-1 receptor agonist market is projected to be valued at US$ 23,854.53 million in 2024 and is expected to rise to US$ 72,127.79 million by 2034. It is expected to grow at a CAGR of 11.7% during the market forecast period.

The GLP-1 receptor agonist market is growing due to the increasing prevalence of diabetes and obesity and the high efficacy of these drugs in managing such conditions.

Key Market Drivers

The market for glucagon-like peptide 1 (GLP-1) agonists offers a potent option for glycemic control, contributing to the growth of the market.
GLP-1 receptor agonists are increasingly attractive for patients and healthcare providers as they are known for their favorable effects on weight loss and low risk of hypoglycemia compared to other diabetes medications.
Extensive clinical research has demonstrated the efficacy and safety of GLP-1 receptor agonists in managing diabetes.
Positive outcomes in glycemic control, cardiovascular risk reduction, and weight management have fueled their adoption in clinical practice.
The convenient dosing regimen of GLP-1 receptor agonists, often administered via injections once a week or less frequently, is expected to boost market demand.
GLP-1 receptor agonists are being explored for their potential in treating obesity, non-alcoholic fatty liver disease (NAFLD), and cardiovascular conditions. Thus, this is contributing to the growth of the market.
Exploring these additional indications broadens the market potential for these drugs.
Competition among pharmaceutical companies has led to continuous innovation in the GLP-1 receptor agonist market.
New formulations with improved pharmacokinetics, delivery systems, and combination therapies are being developed, expanding treatment options and driving market growth.
Patent expirations and the introduction of biosimilar versions may increase affordability and accessibility, further fueling market expansion.

Attributes	Key Statistics
GLP-1 Receptor Agonist Market Value (2024)	US$ 23854.53 million
Anticipated Market Value (2034)	US$ 72127.79 million
Estimated Growth (2024 to 2034)	11.7% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Consumption Analysis in the GLP-1 Receptor Agonist Market

The market for GLP-1 receptor agonists is rising due to the increasing prevalence of diabetes and the need for effective treatments to manage blood sugar levels.
Sales of GLP-1 receptor agonists are increasing, driven by their proven clinical efficacy and safety profile.
Positive outcomes in glycemic control, cardiovascular risk reduction, and weight management boost sales figures.
Healthcare professionals are increasingly adopting GLP-1 receptor agonists as a preferred treatment option for managing diabetes.
The convenience of less frequent dosing and the potential for improved patient compliance contribute to the increasing adoption of GLP-1 receptor agonists.
The popularity of GLP-1 receptor agonists is rising among patients due to their convenient dosing regimens and beneficial effects on weight reduction.
The market for glucagon-like peptide 1 (GLP-1) agonists is rapidly expanding due to continuous innovation and competition among pharmaceutical companies.
New formulations, improved delivery systems, and combination therapies are broadening the market and driving growth.
Patent expirations and the introduction of biosimilar versions are making GLP-1 receptor agonists more accessible and affordable to a wider patient population, further fueling market growth.

Factors Adversely Affecting the GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market is anticipated to surpass a valuation of US$ 72,127.79 million by 2034, expanding at an 11.7% CAGR over the forecast period.

While the GLP-1 receptor agonist market is experiencing growth, several restraining factors can adversely affect its development and expansion.

GLP-1 receptor agonists are effective but expensive, limiting access for patients in regions with limited healthcare coverage or high out-of-pocket expenses.
GLP-1 receptor agonists may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, especially during the initial weeks of treatment.
The development of oral antidiabetic medications provides alternatives to GLP-1 receptor agonists. Some patients may prefer oral medications over injectables, leading to competition within the diabetes treatment landscape.
Regulatory requirements and approval processes for new GLP-1 receptor agonists or indications may pose challenges for pharmaceutical companies, delaying market entry or expansion.
Stringent regulatory standards could hinder the introduction of innovative therapies.
Lack of awareness among healthcare providers and patients about the benefits and the appropriate use of GLP-1 receptor agonists may hinder their uptake.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Category-wise Insights

Type 2 Diabetes Constitutes the Majority of Diabetes Cases Worldwide

Based on indications, type 2 diabetes dominates the GLP-1 receptor agonist market, accounting for a market share of 75.00%. This rising popularity is attributed to the following reasons:

Type 2 diabetes comprises around 90% of all diagnoses. This high prevalence has increased the demand for effective glycemic control and management of associated comorbidities.
GLP-1 receptor agonists have emerged as a valuable therapeutic option for individuals with type 2 diabetes, given their ability to stimulate insulin secretion while suppressing glucagon.
GLP-1 receptor agonists are particularly suitable for individuals with insulin resistance and impaired pancreatic function, common characteristics of type 2 diabetes.
GLP-1 receptor-stimulating agents have a favorable pharmacological profile and can complement other antidiabetic medications.

Attributes	Details
Top Indication	Type 2 Diabetes
Market Share (2024)	75.00%

Expertise, Infrastructure, and Accessibility of Hospital Pharmacies Driving the Market

Based on the distribution channel, hospital pharmacies dominate the market, holding a share of 35.00%. The segment’s rising popularity is attributed to the following aspects:

Hospital pharmacies for specialty medications are usually prescribed by healthcare specialists like endocrinologists or diabetologists.
Due to the complexity of managing diabetes and the need for close monitoring, hospitals are well-equipped to handle the storage, dispensing, and administration of these medications, ensuring proper handling and patient education.
Hospital pharmacies also have established relationships with pharmaceutical manufacturers and wholesalers, enabling efficient procurement and distribution of GLP-1 receptor agonists to meet patient demand.
Hospital pharmacies ensure access to GLP-1 receptor agonists for patients receiving in-patient care or undergoing medical procedures, facilitating optimal disease management and improving patient outcomes.

Attributes	Details
Distribution Channel	Hospital Pharmacies
Market Share (2024)	34.00%

Country-wise Insights

The section analyzes the GLP-1 receptor agonist market by country, including the United Kingdom, China, and India. The table presents the CAGR for each country, indicating the expected market growth in that country through 2034.

Countries	CAGR (2024 to 2034)
India	24.70%
China	23.10%
United Kingdom	12.10%

China's Rapidly Increasing Diabetic Population is among the Highest in the World

China is leading the GLP-1 receptor agonist market. The Chinese market is anticipated to register a CAGR of 23.10% through 2034.

China's urbanization, adoption of sedentary lifestyles, and dietary habits have contributed to the diabetes epidemic.
The Chinese government's healthcare reforms have made innovative medications like GLP-1 receptor agonists more accessible to the public.
As people become more aware of the importance of diabetes management, and with a growing middle-class population seeking better healthcare options, the demand for advanced treatments is expected to rise significantly in China.

India's Genetic Predisposition, Urbanization, and Lifestyle Changes

India is the leading Asian country in the global GLP-1 receptor agonist market, which is anticipated to register a CAGR of 24.70% through 2034.

India has one of the largest diabetic populations globally, and the burden of the disease is continually rising.
India's healthcare landscape is evolving, with increasing awareness about diabetes complications and the importance of early intervention. As a result, there's a growing demand for effective diabetes management strategies, including advanced therapies like GLP-1-based therapy.
With the Indian government's focus on improving healthcare infrastructure and access to innovative treatments, India presents significant growth opportunities for GLP-1 receptor agonist manufacturers.

The United Kingdom's Proactive Approach to Diabetes Management and the Well-Established Healthcare System

The United Kingdom is the leading European country in the GLP-1 receptor agonist market. The market is predicted to register an annual growth rate of 12.10% through 2034.

The United Kingdom has a comprehensive framework for diabetes care, with specialized clinics and a team-based approach involving endocrinologists, diabetes nurse specialists, and dietitians.
The National Health Service (NHS) provides extensive coverage for diabetes treatments, including GLP-1 receptor agonists, ensuring widespread access for eligible patients.
The United Kingdom has witnessed increasing recognition of the importance of early intervention and preventive measures in diabetes care, driving the adoption of innovative treatments.
The United Kingdom continues to prioritize diabetes management and invest in healthcare infrastructure; the demand for GLP-1 receptor agonists is expected to grow, cementing its position as a key market in the global landscape.

Competitive Landscape

Pharmaceutical companies and manufacturers are working hard to increase their market share and profits. They are doing this through various strategies, such as conducting clinical trials to explore the cardiovascular benefits of GLP-1 receptor agonists. They are also studying the effects of medications on pancreatic beta cells and glucagon production to improve overall glycemic control.

With chronic diseases, including diabetes, on the rise globally, pharmaceutical companies are aligning their research and development initiatives with the World Health Organization's recommendations to combat non-communicable diseases.

Continuous product launches and innovations, such as new formulations and combination therapies, aim to expand treatment options and address unmet medical needs in the diabetic population.

Recent Developments

On June 24, 2023, Eli Lilly introduced Orforglipron, an investigational oral daily nonpeptide GLP-1 agonist. Phase-2 studies indicated its comparability with existing injectable and oral agents for treating obesity and type 2 diabetes, potentially revolutionizing treatment options for these conditions.
On October 22, 2023, a study in Scientific Reports detailed the creation of three chimeric GLP-1 receptor agonists. Researchers fused native and mutant GLP-1 with designed ankyrin repeat protein (DARPin), allowing binding to human serum albumin (HSA). These stable, functional molecules showed promise as long-lasting treatments for type 2 diabetes mellitus.
On November 4, 2023, researchers at the University of Tabriz, Iran, developed a groundbreaking long-acting GLP-1 agonist. If clinical trials prove successful, this innovation could extend the duration between treatments for individuals with type 2 diabetes, offering promising advancements in diabetes management.
On August 18, 2023, the emergence of GLP-1 medications like Ozempic, Wegovy, and Mounjaro reshaped the pharmaceutical landscape. Initially designed to manage diabetes, these drugs were found to curb appetites and trigger significant weight loss. As a result, shares of Novo Nordisk and Eli Lilly surged.

Key Companies in the Market

Eli Lilly and Company
Sanofi
Novo-Nordisk A/S
AstraZeneca
Pfizer.Inc
Amgen, Inc.
Innovent Biologics, Inc.
PegBio Co., Ltd
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH

Key Coverage in the GLP-1 Receptor Agonist Market Report

Top 10 GLP-1 Receptor Agonist Drugs Globally
Demand Analysis for GLP-1 Oral Drugs
Comparative Studies in Semaglutide and Ozempic
Ongoing Trends: GLP-1 Drugs for Weight Loss
Insights into GLP-1 Receptor Agonist Mechanism of Action
Corresponding studies on GLP-1 and GLP-2 Drugs

Key Market Segmentation

By Drug Class:

Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Others

By Route of Administration:

Parenteral
Oral

By Indication:

Diabetes
Cardiovascular Disease
Weight Management
Others

By Distribution Channel:

Hospital Pharmacies
Clinics
Ambulatory Surgical Centres

By Region:

Asia Pacific
Europe
North America
Middle East & Africa
Latin America

Frequently Asked Questions

What is the GLP-1 Receptor Agonist Market Valuation in 2024?

The GLP-1 receptor agonist market is predicted to be worth US$ 23,854.53 million in 2024.

What is the Sales Forecast for the GLP-1 Receptor Agonist Market through 2034?

The GLP-1 receptor agonist market is expected to reach US$ 72,127.79 million by 2034.

At What Rate is the GLP-1 Receptor Agonist Market Growing through 2034?

The GLP-1 receptor agonist market is growing at a CAGR of 11.7% from 2024 to 2034.

Which are the Key Companies in the GLP-1 Receptor Agonist Market?

Some of the key players in the market are Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, and Pfizer.Inc., Amgen, Inc., Innovent Biologics, PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, and others.

Which is the Top Indication in the GLP-1 Receptor Agonist Market?

Type-2 diabetes is the top indication, accounting for a market share of 75.00%.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Class, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Class, 2024 to 2034
5.3.1. Exenatide
5.3.2. Liraglutide
5.3.3. Dulaglutide
5.3.4. Lixisenatide
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Route of Administration, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Route of Administration, 2024 to 2034
6.3.1. Parenteral
6.3.2. Oral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Ambulatory Surgical Centres
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2023
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2023
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2023
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2023
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2023
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2023
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2023
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2023
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2023
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2023
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2023
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2023
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2023
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2023
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2023
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2023
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2023
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2023
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2023
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2023
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2023
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2023
16.22.2.1. By Drug Class
16.22.2.2. By Route of Administration
16.22.2.3. By Distribution Channel
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2023
16.23.2.1. By Drug Class
16.23.2.2. By Route of Administration
16.23.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Eli Lilly and Company
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. GlaxoSmithKline plc
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Novo Nordisk A/S
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. PegBio Co., Ltd
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. AstraZeneca
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Intarcia Therapeutics, Inc
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Amylin Pharmaceuticals, Inc
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Sanofi
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Hanmi Pharm. Co., Ltd
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Pfizer Inc
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Amgen Inc
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology

GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Forecast by Hospitals and Clinics from 2024 to 2034